EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A novel selective stabilizer of the ryanodine receptor 2 prevents stress‐induced ventricular arrhythmias without impairing cardiac function

Nagomi Kurebayashi iD, Masami Kodama iD, Hana Inoue iD, Masato Konishi, Masami Sugihara iD, Takashi Murayama iD, Ryosuke Ishida iD, Koichiro Ishii, Shuichi Mori, Yukari Endo iD, Xi Zeng, Yukiko U Inoue iD und 18 weitere

British Journal of Pharmacology · 2026-08 · 183 (15) · 4321-4343

DOI: 10.1111/bph.70459 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 27.04.2026. Verfasst von Nagomi Kurebayashi und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cellular and Molecular Pharmacology, Juntendo University Graduate School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Ryanodine Receptor Calcium Release Channel, Anti-Arrhythmia Agents, Tachycardia, Ventricular, Arrhythmias, Cardiac. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Aberrant activation of type 2 ryanodine receptors (RyR2) causes lethal arrhythmias, such as catecholaminergic polymorphic ventricular tachycardia (CPVT). Developing drugs that suppress RyR2 hyperactivation may be key to novel arrhythmia treatments. This study evaluated the antiarrhythmic potential of Ryanozole, a recently developed novel RyR2 modulator with high affinity and selectivity, using CPVT mouse models harbouring mutant RyR2s. Experimental Approach In vitro effects of Ryanozole were evaluated by endoplasmic reticulum (ER) Ca 2+ ‐based assay and [ 3 H]ryanodine‐binding assay using RyR2‐expressing HEK293 cells. Two lines of mice with different arrhythmia severities, RyR2‐R420W and RyR2‐K4750Q, were employed for in vivo and ex vivo assessments. Intracellular Ca 2+ signals were analysed in isolated cardiomyocytes using Cal‐520. Antiarrhythmic effects were evaluated by electrocardiography (ECG) under catecholaminergic challenge in anaesthetized mice and during spontaneous arrhythmias in conscious mice. ECG and echocardiographic parameters were evaluated before and after drug administration. Key Results Ryanozole inhibited both wild‐type and mutant RyR2s with an IC 50 of 15–40 nM. Inhibition was more potent at lower cytosolic Ca 2+ concentrations. Ryanozole suppressed Ca 2+ waves and Ca 2+ sparks without affecting action potential‐evoked Ca 2+ transients. Ryanozole effectively prevented adrenaline‐induced arrhythmias and rapidly terminated ongoing spontaneous arrhythmias during daily activity. Importantly, Ryanozole did not impair cardiac conduction or contractility, unlike conventional antiarrhythmic drugs. Conclusion and Implications Ryanozole preferentially suppresses RyR2 under diastolic Ca 2+ conditions, thereby preventing the arrhythmogenic trigger of aberrant Ca 2+ release. This mechanism may provide potent antiarrhythmic effects while preserving cardiac function. Ryanozole is a potential therapeutic candidate for RyR2‐mediated arrhythmias, such as CPVT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ryanodine Receptor Calcium Release ChannelAnti-Arrhythmia AgentsTachycardia, VentricularArrhythmias, CardiacAnimalsHumansMiceHEK293 CellsMalePolymorphic Catecholaminergic Ventricular TachycardiaMyocytes, CardiacMice, Inbred C57BLCalcium

Stichwörter der Autor:innen

antiarrhythmic drugscalcium signallingcardiovascular pharmacologycatecholaminergic polymorphic ventricular tachycardiadrug discovery/drug developmentryanodine receptor 2 (RyR2)

Substanzen

Ryanodine Receptor Calcium Release ChannelAnti-Arrhythmia Agentsryanodine receptor 2. mouseCalcium

Autor:innen und Institutionen

  • Department of Cellular and Molecular Pharmacology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Department of Bio-informational Pharmacology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
  • Department of Physiology, Tokyo Medical University, Tokyo, Japan.
  • Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Laboratory for Biomaterials and Bioengineering, Institute of Integrated Research, Institute of Science Tokyo, Tokyo, Japan.
  • National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.

ORCID-Profile: Nagomi Kurebayashi, Masami Kodama, Hana Inoue, Masami Sugihara, Takashi Murayama, Ryosuke Ishida, Yukari Endo, Yukiko U Inoue, Satoru Noguchi, Haruo Ogawa, Kayoko Kanamitsu, Utako Yokoyama, Junko Kurokawa

Zitieren

APA

Kurebayashi, N., Kodama, M., Inoue, H., Konishi, M., Sugihara, M., Murayama, T., Ishida, R., Ishii, K., Mori, S., Endo, Y., Zeng, X., Inoue, Y. U., Inoue, T., Noguchi, S., Nishio, H., Nakashima, E., Suzuki, N., Nakaya, N., Sato, R., …, & Sakurai, T. (2026). A novel selective stabilizer of the ryanodine receptor 2 prevents stress‐induced ventricular arrhythmias without impairing cardiac function. British Journal of Pharmacology, 183(15), 4321-4343. https://doi.org/10.1111/bph.70459

Vancouver

Kurebayashi N, Kodama M, Inoue H, Konishi M, Sugihara M, Murayama T, et al. A novel selective stabilizer of the ryanodine receptor 2 prevents stress‐induced ventricular arrhythmias without impairing cardiac function. British Journal of Pharmacology. 2026;183(15):4321-4343. doi:10.1111/bph.70459

BibTeX
@article{Kurebayashi2026,
  author = {Kurebayashi, Nagomi and Kodama, Masami and Inoue, Hana and Konishi, Masato and Sugihara, Masami and Murayama, Takashi and Ishida, Ryosuke and Ishii, Koichiro and Mori, Shuichi and Endo, Yukari and Zeng, Xi and Inoue, Yukiko U and Inoue, Takayoshi and Noguchi, Satoru and Nishio, Hajime and Nakashima, Eri and Suzuki, Norio and Nakaya, Noriko and Sato, Ryushi and Otori, Yuya and Tsutsumi, Ayuna and Takahashi, Mirei and Oka, Takayuki and Ogawa, Haruo and Kanamitsu, Kayoko and Kusuhara, Hiroyuki and Yokoyama, Utako and Kurokawa, Junko and Kagechika, Hiroyuki and Sakurai, Takashi},
  title = {A novel selective stabilizer of the ryanodine receptor 2 prevents stress‐induced ventricular arrhythmias without impairing cardiac function},
  journal = {British Journal of Pharmacology},
  year = {2026},
  volume = {183},
  number = {15},
  pages = {4321--4343},
  doi = {10.1111/bph.70459}
}
Kostenlos starten →